Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer; it also strikes adults of all ages.
Acute lymphoblastic leukemia (ALL) is a malignant hematopoietic disorder characterized by uncontrolled proliferation of lymphoid progenitor cells. It is the most common pediatric cancer and also affects adults, with distinct cytogenetic subtypes influencing prognosis. Diagnosis relies on marrow blast percentage, cytogenetics, and immunophenotyping. Standard therapy includes multi‑phase chemotherapy, CNS prophylaxis, targeted agents (e.g., TKIs for Ph+ ALL, rituximab for CD20+ B‑ALL), and emerging immunotherapies (blinatumomab, CAR‑T). Outcomes hinge on minimal residual disease status and risk stratification.
ALL is the leading childhood malignancy and poses a significant therapeutic challenge in adults. Understanding its biology, risk factors, and evolving treatment modalities is essential for improving survival and quality of life.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
- Lymphoma Clinical Trials and Research
- Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial
- Englumafusp alfa plus glofitamab in B cell non‑Hodgkin lymphoma: a phase 1 trial